From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of ...

Popular Western medicines for diseases including cancer and diabetes have been caught in the escalating U.S.-China trade war, ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

The FDA granted approval for the use of Skytrofa (lonapegsomatropin) in September 2021 for the treatment of pediatric ...

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

DelveInsight's "TIBSOVO Market Size, Forecast, and Market Insight Report" highlights the details around TIBSOVO, the first ...

Patients with solid tumor malignancies had better survival after ICI therapy if they were obese than if they had a normal BMI.

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization ...

AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

Market capitalisation stands at Rs 19,771.25 crore. The share touched a 52-week high of Rs 9,049.95 and a 52-week low of Rs 5 ...